EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-Metaanalyse

Efficacy of Hypoglycemic Agents in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): A Systematic Review and Network Meta‐Analysis

Qiao Ren, Yao Tan, Guixiang Zhang, Yuzhao Dai, Lidan Yang, Yunmo Wu, He He, Jie Chen iD

Journal of Evidence-Based Medicine · 2025-06 · 18 (2)

DOI: 10.1111/jebm.70021 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Evidence-Based Medicine, online erschienen am 14.04.2025. Verfasst von Qiao Ren und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Fatty Liver. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 78 Literaturangaben. Gefördert von: National Natural Science Foundation of China, 1·3·5 Projects for Artificial Intelligence, West China Hospital, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Metabolic dysfunction associated steatotic liver disease (MASLD) is a universal hepatic disease, and many recent randomized clinical trials (RCTs) have explored whether hypoglycemic agents may be beneficial for its treatment. This study aimed to assess the relative effectiveness of each hypoglycemic agent for MASLD.

Methods

China National Knowledge Infrastructure(CNKI), WanFang, Weipu, PubMed, Embase, The Cochrane Library, and Web of Science Core Collection were searched for RCTs on the efficacy of hypoglycemic agents in MASLD published up to December 31, 2024. All statistical analyses were performed using R version 4.3.3. The network meta‐analysis was conducted using Bayesian statistical methods.

Results

A total of 26 hypoglycemic agents for treating MASLD in 37 studies with 2406 participants were included. Empagliflozin was most effective in improving liver stiffness measurement (LSM), whereas liraglutide showed significant benefits in body weight, body mass index (BMI), and waist circumference. Both sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors (e.g., empagliflozin) and glucagon‐like peptide‐1 (GLP‐1) receptor agonists (e.g., liraglutide) improved liver enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma‐glutamyltransferase [GGT]), glucose metabolism (fasting plasma glucose [FPG], and homeostasis model assessment of insulin resistance [HOMA‐IR]), and lipid profiles. Pioglitazone had limited benefits in these outcomes. Secondary outcomes such as inflammatory markers and fibrosis showed minimal changes.

Conclusions

Several hypoglycemic agents can improve laboratory and imaging indicators in adult patients with MASLD. Liraglutide is more effective than other agents, whereas empagliflozin emerged as the most effective for reducing LSM. However, different agents have different effects on the indicators; therefore, the relevant agents must be selected according to the specific patient condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoglycemic AgentsFatty LiverHumansSodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsGlucosidesRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

hypoglycemic agentsmetabolic dysfunction associated steatotic liver disease (MASLD)network meta‐analysis

Substanzen

Hypoglycemic AgentsempagliflozinSodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsGlucosides

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Medical Genetics, West China Second University Hospital, Sichuan University, Chengdu, China.
  • Sichuan Clinical Research Center for Laboratory Medicine, Chengdu, China.
  • Clinical Laboratory Medicine Research Center of West China Hospital, Chengdu, China.
  • Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Jie Chen

Förderung

  • National Natural Science Foundation of China
  • 1·3·5 Projects for Artificial Intelligence, West China Hospital, Sichuan University

Zitieren

APA

Ren, Q., Tan, Y., Zhang, G., Dai, Y., Yang, L., Wu, Y., He, H., & Chen, J. (2025). Efficacy of Hypoglycemic Agents in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): A Systematic Review and Network Meta‐Analysis. Journal of Evidence-Based Medicine, 18(2). https://doi.org/10.1111/jebm.70021

Vancouver

Ren Q, Tan Y, Zhang G, Dai Y, Yang L, Wu Y, et al. Efficacy of Hypoglycemic Agents in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): A Systematic Review and Network Meta‐Analysis. Journal of Evidence-Based Medicine. 2025;18(2). doi:10.1111/jebm.70021

BibTeX
@article{Ren2025,
  author = {Ren, Qiao and Tan, Yao and Zhang, Guixiang and Dai, Yuzhao and Yang, Lidan and Wu, Yunmo and He, He and Chen, Jie},
  title = {Efficacy of Hypoglycemic Agents in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): A Systematic Review and Network Meta‐Analysis},
  journal = {Journal of Evidence-Based Medicine},
  year = {2025},
  volume = {18},
  number = {2},
  doi = {10.1111/jebm.70021}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche